Changing pattern of adenocarcinoma of the esophagogastric junction in recent 10 years: Experience at a large tertiary medical center in China

Tumori

Volumn 98, Issue 5, 2012, Pages 568-574

  Wang, Kun ^a   Yang, Chang Qing ^a   Duan, Li Ping ^a   Yang, Xue Song ^a   Xia, Zhi Wei ^a   Cui, Rong Li ^a   Jin, Zhu ^a   McNutt, Michael ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Adenocarcinoma of the esophagogastric junction; Changing pattern; Reflux esophagitis

Indexed keywords

ADENOCARCINOMA; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CHINA; COHORT ANALYSIS; CORRELATION ANALYSIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGOGASTRIC ADENOCARCINOMA; FEMALE; GASTRIC NONCARDIAC ADENOCARCINOMA; GASTROINTESTINAL TUMOR; GASTROSCOPY; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; REFLUX ESOPHAGITIS; TERTIARY HEALTH CARE; TREND STUDY;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHINA; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOGASTRIC JUNCTION; FEMALE; GASTRECTOMY; GASTROSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; STOMACH NEOPLASMS; SURVIVAL RATE; TERTIARY CARE CENTERS;

EID: 84872090839     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/1190.13196     Document Type: Article

References (39)

1. Jemal A, Murray T, Ward E: Cancer statistics, CA Cancer J Clin, 55: 10-30, 2005.
2. Chung JW, Lee GH, Choi KS, Kim DH, Jung KW, Song HJ, Choi KD, Jung HY, Kim JH, Yook JH, Kim BS, Jang SJ: Unchanging trend of esophagogastric junction adenocarcinoma in Korea: experience at a single institution based on Siewert's classification. Dis Esophagus, 22: 676-681, 2009.
3. Kusano C, Gotoda T, Khor CJ, Katai H, Kato H, Taniguchi H, Shimoda T: Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol, 23: 1662-1665, 2008.
4. Hasegawa S, Yoshikawa T: Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies. Gastric Cancer, 13: 63-73, 2010.
5. Zhou Y, Zhang Z, Zhang Z, Wu J, Ren D, Yan X, Wang Q, Wang Y, Wang H, Zhang J, Zhu X, Yang Y, Luo C, Guo X, Tang C, Qiao L: A rising trend of gastric cardia cancer in the Gansu Province of China. Cancer Lett, 269: 18-25, 2008.
6. Stein HJ, Feith M, Siewert JR: Cancer of the esophagogastric junction. Surg-Oncol, 9: 35-41, 2000.
7. Bai JG, Lv Y, Dang CX: Adenocarcinoma of the esophagogastric junction in China according to Siewert's classification. Jpn J Clin Oncol, 36: 364-367, 2006.
8. Sun Q, Liu C, Zhong H, Zhong B, Xu H, Shen W, Wang D: Multi-center phase II trial of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric and gastro-esophageal cancer. Jpn J Clin Oncol, 39: 237-243, 2009.
9. Wei S, Tian J, Song X, Chen Y: Association of perioperative fluid balance and adverse surgical outcomes in esophageal cancer and esophagogastric junction cancer. Ann Thorac Surg, 86: 266-272, 2008.
10. Zhang X, Watson DI, Jamieson GG: Lymph node metastases of adenocarcinoma of the esophagus and esophagogastric junction. Chin Med J (Engl), 120: 2268-2270, 2007.
11. Huang Q, Zhang LH: The histopathologic spectrum of carcinomas involving the gastroesophageal junction in the Chinese. Int J Surg Pathol, 15: 38-52, 2007.
12. Lagergren J, Bergström R, Lindgren A, Nyrén O: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. NEJM, 340: 825-831, 1999.
13. Inomata Y, Koike T, Ohara S, Abe Y, Sekine H, Iijima K, Ariizumi K, Yamagishi H, Kitagawa Y, Imatani A, Shimosegawa T: Preservation of gastric acid secretion may be important for the development of gastroesophageal junction adenocarcinoma in Japanese people, irrespective of the H. pylori infection status. Am J Gastroenterol, 101: 926-933, 2006.
14. Chak A, Falk G, Grady WM, Kinnard M, Elston R, Mittal S, King JF, Willis JE, Kondru A, Brock W, Barnholtz-Sloan J: Assessment of familiality, obesity, and other risk factors for early age of cancer diagnosis in adenocarcinomas of the esophagus and gastroesophageal junction. Am J Gastroenterol, 104: 1913-1921, 2009.
15. Merry AH, Schouten LJ, Goldbohm RA, van den Brandt PA: Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study. Gut, 56: 1503-1511, 2007.
16. Layke JC, Lopez PP: Esophageal cancer: a review and update. Am Family Phys, 73: 2187-2194, 2006.
17. Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P: Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a metaanalysis. Gastrointest Endosc, 67: 394-398, 2008.
18. Schneider PM: Adenocarcinomas of the Esophagogastric Junction, p 238, Springer, 2010.
19. Armstrong D, Bennett JR, Blum AL, Dent J, De Dombal FT, Galmiche JP, Lundell L, Margulies M, Richter JE, Spechler SJ, Tytgat GN, Wallin L: The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology, 111: 85-92, 1996.
20. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer, 54: 594-606, 1993.
21. Crew KD, Neugut AI: Epidemiology of gastric cancer. World J Gastroenterol, 12: 354-362, 2006.
22. Cook MB, Chow WH, Devesa SS: Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer, 101: 855-859, 2009.
23. Marsman WA, Tytgat GN, ten Kate FJ, van Lanschot JJ: Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction J Surg Oncol, 92: 160-168, 2005.
24. Van Dekken H, Geelen E, Dinjens WN, Wijnhoven BP, Tilanus HW, Tanke HJ, Rosenberg C: Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardiac adenocarcinomas. Cancer Res, 59: 748-752, 1999.
25. Cameron AJ, Souto EO, Smyrk TC: Small adenocarcinomas of the esophagogastric junction: association with intestinal metaplasia and dysplasia. Am J Gastroenterol, 97: 1375-1380, 2002.
26. Hirota WK, Loughney TM, Lazas DJ, Maydonovitch CL, Rholl V, Wong RK: Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogasric junction: prevalence and clinical data. Gastroenterology, 116: 277-285, 1999.
27. Zhai R, Chen F, Liu G, Su L, Kulke MH, Asomaning K, Lin X, Heist RS, Nishioka NS, Sheu CC, Wain JC, Christiani DC: Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J Clin Oncol, 28: 2445-2451, 2010.
28. Shaheen N, Ransohoff DF: Gastroesophageal reflux, Barrett esophagus and esophageal cancer. JAMA, 287: 1972-1981, 2002.
29. Fass R: Non-erosive reflux disease (NERD) and erosive esophagitis - a spectrum of disease or special entities? Z Gastroenterol, 45: 1156-1163, 2007.
30. Wang K, Duan LP, Chen H, Xia ZW, Lin SR: Comparison of esophageal acid exposure characteristics between reflux oesophagitis and non-erosive reflux diseases. Chin J Inter Med, 44: 5-8, 2005.
31. Asaoka D, Miwa H, Hirai S, Ohkawa A, Kurosawa A, Kawabe M, Hojo M, Nagahara A, Minoo T, Ohkura R, Ohkusa T, Sato N: Altered localization and expression of tight-junction proteins in a rat model with chronic acid reflux esophagitis. J Gastroenterol, 40: 781-790, 2005.
32. Souza RF, Huo X, Mittal V, Schuler CM, Carmack SW, Zhang HY, Zhang X, Yu C, Hormi-Carver K, Genta RM, Spechler SJ: Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology, 137: 1776-1784, 2009.
33. Coussens LM, Werb Z: Inflammation and cancer. Nature, 420: 860-867, 2002.
34. Parsonnet J, Friedman GD, Orentreich N, Vogelman H: Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut, 40: 297-301, 1997.
35. Ye W, Held M, Lagergren J, Engstrand L, Blot WJ, McLaughlin JK, Nyrén O: Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Caner Inst, 96: 388-396, 2004.
36. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G: Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol, 5: 1413-1417.e1-2, 2007.
37. Whiteman DC, Parmar P, Fahey P, Moore SP, Stark M, Zhao ZZ, Montgomery GW, Green AC, Hayward NK, Webb PM: Australian Cancer Study. Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers. Gastroenterology, 139: 73-83, 2010.
38. Anderson LA, Murphy SJ, Johnston BT, Watson RG, Ferguson HR, Bamford KB, Ghazy A, McCarron P, McGuigan J, Reynolds JV, Comber H, Murray LJ: Relationship between Helicobacter pylori infection and gastric atrophy and the stages of the oesophageal inflammation, metaplasia, adenocarcinoma sequence: results from the FINBAR casecontrol study. Gut, 57: 734-739, 2008.
39. Koike T, Ohara S, Sekine H, Iijima K, Abe Y, Kato K, Toyota T, Shimosegawa T: Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut, 49: 330-334, 2001.